This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB09018/identifier/chebi/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/drug/DB09018/identifier/wikipedia/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB09018/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/patent/
n17http://linked.opendata.cz/resource/drugbank/drug/DB09018/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://www.drugs.com/international/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09018
rdf:type
n3:Drug
n3:description
Bromopride is a dopamine antagonist with prokinetic properties closely related to metoclopramide, and is widely used as an antiemetic. It is not available in the United States or the United Kingdom.
n3:group
approved
n3:indication
Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract.
owl:sameAs
n9:DB09018
dcterms:title
Bromopride
adms:identifier
n14:D07101 n15:Bromopride n16:310957 n17:DB09018
n3:patent
n10:3177252 n10:3219528 n10:3357978
n3:synonym
Bromoprid Bromoprida 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Bromopride Bromopridum
n3:proteinBinding
40%.
n3:synthesisReference
U.S. Patents 3,177,252; 3,219,528; and 3,357,978.
foaf:page
n12:bromopride.html
n3:IUPAC-Name
n4:271B6535-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B653B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B653A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6537-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6538-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6539-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6533-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6531-363D-11E5-9242-09173F13E4C5 n4:271B6534-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6532-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:A03FA04
n3:H-Bond-Acceptor-Count
n4:271B6541-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6542-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B653C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B653D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B653F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B653E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6540-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
4093-35-0
n3:clearance
Renal, 10-14% as original compound.
n3:Bioavailability
n4:271B6547-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6549-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B654A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B654B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6546-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6545-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6548-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6536-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6543-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6544-363D-11E5-9242-09173F13E4C5